Telangana has announced an ambitious roadmap to transform itself into one of the world’s leading life sciences destinations with the launch of its Next-Gen Life Sciences Policy 2026–2030. The policy was unveiled at a global economic forum and reflects the state’s long-term vision to evolve from a volume-driven pharmaceutical base into a high-value therapy and innovation-led life sciences ecosystem.
With a target of $25 billion in investments and the creation of 5 lakh high-quality jobs by 2030, the policy aims to strengthen Telangana’s position in the global pharmaceutical, biotechnology, and healthcare innovation landscape.
A Strategic Shift Toward High-Value Therapies
For decades, Telangana has played a vital role in India’s pharmaceutical manufacturing ecosystem, particularly in large-scale production. The new life sciences policy marks a clear shift from volume-based manufacturing to high-value therapies, advanced research, and innovation-driven growth.
The policy focuses on emerging and future-ready segments such as:
-
Biologics and biosimilars
-
Cell and gene therapies
-
Precision medicine
-
Digital health solutions
-
Data-driven drug discovery
This strategic transition will enable the state to compete with established global life sciences hubs while delivering higher economic value and skilled employment opportunities.
Strengthening the Clinical Trial Ecosystem
A robust clinical research environment is essential for innovation in life sciences. Recognising this, the policy introduces comprehensive measures to strengthen the clinical trial ecosystem across the state.
Key initiatives include:
-
Faster and more transparent clinical trial approvals
-
Development of disease-specific clinical registries
-
Implementation of a Clinical Innovation Sandbox to support real-world testing
These steps aim to reduce approval timelines, encourage international clinical research activity, and accelerate the journey from research to market-ready therapies.
Development of Pharma Villages for Balanced Growth
A standout feature of the policy is the development of 10 integrated pharma villages, each covering 1,000 to 3,000 acres, strategically located along the Outer Ring Road.
The objectives of these pharma villages include:
-
Decentralised and inclusive industrial development
-
Reduced pressure on urban infrastructure
-
Cluster-based manufacturing efficiency
-
Opportunities for small and medium-scale enterprises
By promoting distributed industrial growth, Telangana is ensuring long-term sustainability while expanding its manufacturing footprint across the state.
Bio-Innovation and Bio-Manufacturing Clusters
To support innovation-led manufacturing, the policy proposes the creation of a bio-innovation and bio-manufacturing cluster in collaboration with national-level institutions.
This cluster will serve as a catalyst for:
-
Research-driven startups
-
Technology commercialisation
-
Collaborative product development
-
Scale-up support for emerging enterprises
Such infrastructure is expected to benefit organisations focusing on specialised product portfolios, including those aligned with the concept of a monopoly medicine company in India, where innovation and differentiation play a key role in market leadership.
Regulatory Reforms and Ease of Doing Business
To address regulatory bottlenecks, the policy places strong emphasis on ease of doing business through systemic reforms.
Major highlights include:
-
Permission for 24×7 operations in designated life sciences parks
-
A dedicated consultation committee to streamline regulatory clearances
-
Simplified state-level approvals
-
A single-window clearance system with time-bound approvals and deemed approvals in case of delays
These reforms significantly reduce administrative uncertainty and improve investor confidence in the state’s regulatory environment.
Focus on Global Innovation and Advanced Technologies
Building on its growing reputation as a destination for global capability centres, Telangana aims to move further up the value chain by developing Global Innovation Centres.
These centres will focus on:
-
Artificial intelligence and advanced analytics
-
Engineering and digital health platforms
-
High-end research and development in healthcare
-
Data-driven life sciences innovation
This convergence of technology and healthcare will strengthen the state’s position as a preferred destination for partnerships with a pharma contract manufacturing company that demands advanced infrastructure, compliance readiness, and technological integration.
Employment Generation and Investment Outlook
Beyond infrastructure and innovation, the policy places strong emphasis on employment generation. The target of 5 lakh skilled jobs includes roles across research, manufacturing, quality assurance, regulatory affairs, data science, and digital health.
With clear policy direction, strong governance mechanisms, and investor-friendly reforms, Telangana is positioning itself as a long-term, stable destination for life sciences investment.
Conclusion
The Next-Gen Life Sciences Policy 2026–2030 represents a transformative vision for Telangana’s pharmaceutical and biotechnology ecosystem. By focusing on high-value therapies, strengthening clinical research, enabling decentralised manufacturing, and simplifying regulatory processes, the state is laying the foundation for sustainable, innovation-driven growth.
As global demand for advanced healthcare solutions continues to rise, Telangana’s policy-driven approach places it firmly on the path to becoming one of the world’s most competitive and trusted life sciences hubs by 2030.